SalioGen Therapeutics Appoints Esteemed Industry Veterans to Executive Advisory Board

John Maraganore, Ph.D., Mark McClellan, M.D., Ph.D. and Andrew Lo, Ph.D. appointed as Executive Advisors to support SalioGen’s efforts to realize the full potential of its novel Gene CodingTM platform

CAMBRIDGE, Mass. – November 10, 2021 – SalioGen Therapeutics, a privately held biotechnology company developing the Gene CodingTM approach to genetic medicine, announced today the formation of an Executive Advisory Board (EAB) led by John Maraganore, Ph.D., Mark McClellan, M.D., Ph.D. and Andrew Lo, Ph.D. The EAB will work closely with the executive management team in building SalioGen’s sustainable and multidisciplinary strategy and guiding the company as it advances its Gene Coding platform through multiple therapeutic areas.

“We are extremely privileged to have the opportunity to tap into the expertise of these three esteemed veterans as we work to build a transformative, patient-centric and science-driven company,” said Ray Tabibiazar, M.D., Chairman and Chief Executive Officer of SalioGen. “John’s experience building an exceptionally successful platform company based on a new category of medicine will be invaluable as we begin our journey down a similar road. Additionally, Mark’s unparalleled command of regulatory and healthcare policy will be crucial as we begin to navigate an evolving regulatory landscape with a novel technology. Finally, Andrew’s research and deep understanding of financial markets will be paramount in guiding our disciplined and thoughtful approach to advancing our Gene Coding genetic medicine platform. We’re confident that these three experts, in addition to our established management and board members, will position SalioGen for success.”

Dr. Maraganore, long-tenured, founding Chief Executive Officer (CEO) of Alnylam Pharmaceuticals, led the advancement of RNA interference (RNAi) from an early platform technology into a new, validated class of genetic medicines. While he was CEO, Alnylam received approval for four medicines in over 25 countries, including the first ever approval for an RNAi therapeutic. Prior to Alnylam, he served in senior roles for various other companies, including Millennium Pharmaceuticals and Biogen.

Dr. Maraganore said, “SalioGen’s approach is highly differentiated and has exciting prospects for new medicines. I see many similarities between the opportunities and challenges at Alnylam in years past and those SalioGen faces today, as they embark on a journey of building a product engine platform around their scientific discovery. I look forward to advising the SalioGen team in their advancement of Gene Coding, with the goal of bringing treatments and potentially cures to patients with their breakthrough technology.”

Dr. McClellan, former commissioner of the U.S. Food and Drug Administration (FDA) and former administrator of the Centers for Medicare & Medicaid Services (CMS), has led the development and reformation of health policy at the highest levels. He currently serves as the Robert J. Margolis Professor of Business, Medicine, and Policy, and founding Director of the Duke-Margolis Center for Health Policy at Duke University.

Dr. McClellan added, “Genetic medicines and cellular therapies represent major new opportunities to intercept and cure diseases, and as such, they require thoughtful attention to demonstrating safety and effectiveness, and to assuring that patients who can benefit get access at a sustainable cost. I’m pleased to provide guidance to the distinguished team at SalioGen as they work to develop a truly innovative approach for improving the lives of patients.”

Dr. Lo, award-winning economist and Co-Founder of BridgeBio Pharma, has spent his career refining a multidisciplinary approach to understanding financial markets, including healthcare finance. Dr. Lo is the Charles E. and Susan T. Harris Professor of Finance and the Director of the Laboratory for Financial Engineering at the MIT Sloan School of Management. He is published extensively and has won dozens of awards for his research.

Dr. Lo added, “Navigating therapeutics development as an early-stage biotech company is a nuanced challenge even in the most forgiving economic circumstances. I’m thrilled to lend my years of research to assess SalioGen’s platform opportunity using big data and apply a strategic and analytical approach to its pipeline and portfolio prioritization.”

About SalioGen Therapeutics

SalioGen Therapeutics has launched Gene CodingTM, a genetic medicine platform, to develop durable, broadly applicable genetic medicines, using its Exact DNA Integration TechnologyTM (EDIT) platform. EDIT™ is based on the novel discovery of a mammal-derived genomic engineering tool, for use in potentially curative genetic medicines. SalioGen is focused on developing durable, safe and accessible non-viral genetic medicines for more patients with inherited diseases that are beyond what is addressable with current technologies, initially focusing on inherited macular disorders and inherited lipid disorders.

For more information, please visit www.saliogen.com, or follow us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements. Words such as “may,” “believe,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are based upon current estimates and assumptions and include statements regarding the contributions to be made by each of the additions to the Executive Advisory Board and the potential of SalioGen’s Gene Coding approach, including its use in potentially curative genetic medicines. While SalioGen believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of Drs. John Maraganore, Ph.D., Mark McClellan, M.D., Ph.D. and Andrew Lo, Ph.D. to position SalioGen for success and the ability of SalioGen to use its evolved approach to gene therapy, based on a mammal-derived genetic engineering tool in potentially curative genetic medicines and to develop durable, safe and accessible therapeutics to more patients with inherited diseases that are beyond what is addressable with current gene therapies. All forward-looking statements are based on SalioGen’s expectations and assumptions as of the date of this press release. Actual results may differ materially from these forward-looking statements. Except as required by law, SalioGen expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.

Corporate Contact:

Sung You, M.S., MBA
SalioGen Therapeutics
[email protected]

Media Contact:

Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192
[email protected]icomms.com